Ixekizumab as treatment of erythrodermic psoriasis

2021 ◽  
Vol 34 (2) ◽  
Author(s):  
Emanuele Trovato ◽  
Corinne Orsini ◽  
Filomena Russo ◽  
Giulio Cortonesi ◽  
Pietro Rubegni
Keyword(s):  
Erythrodermic Psoriasis

Two cases of refractory erythrodermic psoriasis effectively treated with secukinumab and a review of the literature

2021 ◽  
Author(s):  
Luo‐Chen Liu ◽  
Xian‐Hua Jin ◽  
ChunLei Sun ◽  
Jian‐Xin Xia
Keyword(s):  
Review Of The Literature ◽  
Erythrodermic Psoriasis

Distribution of T-cell subpopulations in the peripheral blood of patients with erythrodermic psoriasis

1984 ◽  
Vol 277 (1) ◽  
pp. 19-23 ◽  
Author(s):  
R. Willemze ◽  
W. J. M. Damsteeg ◽  
C. J. L. M. Meijer
Keyword(s):  
T Cell ◽  
Peripheral Blood ◽  
Erythrodermic Psoriasis ◽  
Cell Subpopulations ◽  
T Cell Subpopulations

The buccal mucosa in erythrodermic psoriasis

1985 ◽  
Vol 10 (5) ◽  
pp. 495-498 ◽  
Author(s):  
R.A. DENDY ◽  
G.B. WALKER ◽  
P.V. HARRISON
Keyword(s):  
Buccal Mucosa ◽  
Erythrodermic Psoriasis

Treatment of Erythrodermic Psoriasis with Etretinate

1991 ◽  
Vol 3 (2) ◽  
pp. 107 ◽  
Author(s):  
Bang Soon Kim ◽  
Ki Shik Shin ◽  
Jai Il Youn ◽  
Yoo Shin Lee
Keyword(s):  
Erythrodermic Psoriasis

scholarly journals Palmoplantar psoriasis: a comparative therapeutic study

2019 ◽  
Vol 5 (4) ◽  
pp. 779
Author(s):  
Sathya Narayanan Rajendran ◽  
Sukanya Mathupal Gurusamy
Keyword(s):  
Treatment Options ◽  
Clinical Manifestations ◽  
Simple Random Sampling ◽  
Inflammatory Dermatosis ◽  
Duration Of Illness ◽  
Erythrodermic Psoriasis ◽  
Life Threatening ◽  
Group A ◽  
Group B ◽  
Therapeutic Study

<p class="abstract"><strong>Background:</strong> Psoriasis is an immunologically mediated inflammatory dermatosis presenting with extremely variable clinical manifestations ranging from indolent lesions to life threatening forms of pustular and erythrodermic psoriasis. Palmoplantar psoriasis present as hyperkeratotic scaly plaques with fissures and can be managed with different treatment forms. This study was done to compare the efficacy between topical and systemic treatment options.</p><p class="abstract"><strong>Methods:</strong> The study was conducted in a tertiary level teaching hospital after ethical committee clearance. Fifty patients with palmoplantar psoriasis were allocated into the two groups using simple random sampling. PPPASI scoring was calculated to assess the extent of involvement. Patients in Group A were prescribed calcipotriol with clobetasol propionate ointment. Group B patients were given tablet methotrexate.<strong></strong></p><p class="abstract"><strong>Results:</strong> Twenty eight patients were males M: F of 1.27: 1. Mean age was 36. Mean duration of illness was eleven months. Most of these patients were manual laborers. 32 patients had lesions over both palms and soles, 9 over palms alone and 9 involving soles alone. Mean PASI reduction at 16 weeks was seen maximum with methotrexate. Compliance was comparatively good with methotrexate than topical. Though mean PASI reduction and compliance was good, relapse rates were higher with methotrexate in our study.</p><p class="abstract"><strong>Conclusions:</strong> There was no significant change in clinico-epidemiology and presentation of palmoplantar psoriasis. Methotrexate was observed to be the more efficacious modality in treating palmoplantar psoriasis.</p>

Use of secukinumab in erythrodermic psoriasis: A single center experience

2021 ◽  
Author(s):  
Anuj Bhatnagar ◽  
Gautam Kumar Singh ◽  
Sanjeev Kumar Deshpande ◽  
Barnali Mitra ◽  
Debdeep Mitra ◽  
...  
Keyword(s):  
Single Center ◽  
Single Center Experience ◽  
Erythrodermic Psoriasis

scholarly journals Targeted Treatment for Erythrodermic Psoriasis: Rationale and Recent Advances

Drugs ◽  
2020 ◽  
Vol 80 (6) ◽  
pp. 525-534 ◽  
Author(s):  
Shuai Shao ◽  
Gang Wang ◽  
Emanual Maverakis ◽  
Johann E. Gudjonsson
Keyword(s):  
Targeted Treatment ◽  
Recent Advances ◽  
Erythrodermic Psoriasis
Sign in / Sign up

Export Citation Format

Share Document